APA

Vugmeyster Y., Kikuchi T., Lowes M. A., Chamian F., Kagen M., Gilleaudeau P., Lee E., Howell K., Bodary S., Dummer W. & Krueger J. G. (20041026). Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. : Clinical immunology (Orlando, Fla.).

Chicago

Vugmeyster Yulia, Kikuchi Toyoko, Lowes Michelle A, Chamian Francesca, Kagen Mark, Gilleaudeau Patricia, Lee Edmund, Howell Kathy, Bodary Sarah, Dummer Wolfgang and Krueger James G. 20041026. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. : Clinical immunology (Orlando, Fla.).

Harvard

Vugmeyster Y., Kikuchi T., Lowes M. A., Chamian F., Kagen M., Gilleaudeau P., Lee E., Howell K., Bodary S., Dummer W. and Krueger J. G. (20041026). Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. : Clinical immunology (Orlando, Fla.).

MLA

Vugmeyster Yulia, Kikuchi Toyoko, Lowes Michelle A, Chamian Francesca, Kagen Mark, Gilleaudeau Patricia, Lee Edmund, Howell Kathy, Bodary Sarah, Dummer Wolfgang and Krueger James G. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. : Clinical immunology (Orlando, Fla.). 20041026.